secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantheus Holdings, Inc. (LNTH)
CIK:        0001521036
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001628280-25-007965
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantheus Q4 revenue $391M (+10.5%); GAAP EPS $(0.17), adj. EPS $1.59; FY25 guide $1.55B-$1.61B
--------------------------------------------------------------------------------

- Q4 revenue $391.1M (+10.5% YoY); PYLARIFY $266M (+15.7%), DEFINITY $86.2M (+17.9%).
- GAAP fully diluted EPS $(0.17) vs $1.47 prior; adj. EPS $1.59 (-9% YoY).
- Agreements to acquire Life Molecular (Alzheimer's radiodiagnostic) and Evergreen Theragnostics (manufacturing), expected H2 2025.
- CMS final 2025 OPPS rule grants separate payment for PYLARIFY and other diagnostic radiopharmaceuticals.
- FY 2025 revenue guidance $1.545B-$1.610B; adjusted EPS guidance $7.00-$7.20.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1521036/000162828025007965/0001628280-25-007965-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1521036/000162828025007965/lnth-20250226.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-007965

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer